This article is more than 5 years old. Information may no longer be current.
Similar results seen in PsA patients treated with etanercept alone or in combination with methotrexate
Click Here to Manage Email Alerts
Similar proportions of patients with psoriatic arthritis who received monotherapy with etanercept compared to patients who received both etanercept and methotrexate met the psoriatic arthritis response criteria and few between-group differences were seen, according to recently published data.
Researchers studied 322 patients in an intention-to-treat group who received etanercept (Enbrel, Amgen) and 152 patients who received etanercept and methotrexate. Baseline demographics were similar between the groups. Mean disease duration was 18.4 years for the monotherapy group vs. 17.5 years for the comparison group.
Most measured outcomes were similar between the monotherapy and dual therapy treatment groups. The psoriatic arthritis (PsA) Response Criteria was met by 80.3% who received monotherapy and by 82.6% of patients who received both etanercept and methotrexate, while greater proportions of patients who received monotherapy met ACR50 responses (54.9% vs. 48.3%). Both groups met around a 70% ACR20 response.
Skin responses were similar in both groups, as were improvements in the Health Assessment Questionnaire-Disability Index responses at week 24.
“Further research is warranted to better understand the potential advantages and disadvantages of [methotrexate] MTX use with anti-[tumor necrosis factor] TNF therapy for PsA,” the researchers wrote.
Disclosure: The researchers report the work was sponsored by Pfizer.
Collapse
Combe B, et al. J Rheumatol. 2016;doi10.3899/jrheum.151290.
Click Here to Manage Email Alerts